Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-05-06
2009-08-11
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S546000, C514S640000, C514S679000
Reexamination Certificate
active
07572825
ABSTRACT:
The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae: (1) (2) wherein: Ar1is independently a biphenyl, phenanthryl, fluorenyl, or carbazolyl, and is optionally substituted; Ralkis independently a C2-10alkylene group, and is optionally substituted; —ORO, if present, is independently —OH or —ORK; —ORK, if present, is independently selected from: —O—RK1; —O—C(═O)RK2; —O—C(═O)ORK3; —O—S(═O)2ORK4; Q is independently —OH or —OROT; wherein: —OROT, if present, is independently selected from: —O—RE1; —O—C(═O)—RE2; —O—C(═O)—O—RE3; —O—C(═O)—O—SO3RE4; —O—C(═O)—O—(CH2)n—COORE5; —O—C(═O)—(CH2)n—NRN1RN2; —O—C(═O)—(CH2)n—NH—C(═O)RE6; —O—C(═O)—(CH2)n—C(═O)—NRN3RN4; —O—P(═O)(ORE7)(ORE8); —O—RPA; RPA, if present, is an organic group which incorporates a phosphonic acid group; with the proviso that if —OROTis —O—RE1, then RE1is not a phenyl group substituted with a sulfonyl group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, or prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.
REFERENCES:
patent: 4017416 (1977-04-01), Inukai et al.
patent: 5859047 (1999-01-01), Kluender et al.
patent: 2005/0119305 (2005-06-01), Naka et al.
patent: 1 215 203 (2002-06-01), None
patent: 11-80107 (1999-03-01), None
patent: 2001-352978 (2001-12-01), None
patent: WO 97/10247 (1997-03-01), None
patent: WO 97/41099 (1997-11-01), None
patent: WO 02/074298 (2002-09-01), None
patent: WO 02/092588 (2002-11-01), None
patent: WO 03/037321 (2003-05-01), None
Armour K.J., et al., 2001, “Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026),”Arthritis and Rheumatism, vol. 44, No. 9, pp. 2185-2192.
Boots, M.R., et al, 1973 “Hypocholesterolemic Agents II: Inhibition of β-Hydroxy-β-Methylglutaryl Coenzyme A Reductase by Arylalkyl Hydrogen Succinates and Glutarates”,J. Pharm. Sci., vol. 62, No. 6, pp. 952-57.
Boots, M.R., et al, 1976, “Hypocholesterolemic Agents IV: Inhibition of β-Hydroxy-β-Methylglutaryl Coenzyme A Reductase by Arylalkenyl and Arylepoxy Hydrogen Succinates and Glutarates”,J. Pharm. Sci., vol. 65, No. 5, pp. 724-727.
Coxon, F.P., et al., 2000, “Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298,”J.Bone Miner.Res., vol. 15, pp. 1467-1476.
Degenhardt, C.R., et al., 1986, “Synthesis of Ethenylidenebis (phosphonic acid) and its Tetraalkyl Esters,”J. Org. Chem., vol. 51, pp. 3488-3490.
Eberhard, A., et al., 1965, “Hydrolysis of Phostonates,”J. Amer. Chem. Soc., vol. 87, pp. 253-260.
Herczegh, P., et al, 2002, “Osteoadsorptive Bisphosphonate Derivatives of Fluoroquinolone Antibacterials,”J. Med. Chem., vol. 45, pp. 2338-2341.
Hughes, D.E., et al., 1997, “Apoptosis in bone physiology and disease,”Molecular Pathology, vol. 50, pp. 132-137.
Kong, Y.Y., et al., 1999, “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,”Nature, vol. 397, pp. 315-323.
Kudo, O., et al., 2003, “Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism”,Bone, vol. 32, No. 1, pp. 1-7.
Kusano, K., et al, 1998, “Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption”,Endocrinology, vol. 139, No. 3, pp. 1338-1345.
Luckman, et al., 1998, “Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure- activity relationships in J774 macrophages,”J. Bone Miner. Res., vol. 13, pp. 1668-1678.
MacPherson, H; et al., 1999, “Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells,”Bone, vol. 24, pp. 179-185.
Mai, A., et al, 1997, “Arylketotetramethylene analogues of disoxaril and anti-human rhinovirus 14 activity”,Antiviral Chemistry&Chemotherapy, vol. 8, No. 3, pp. 235-242.
Mundy, G.R., 1996, “Chapter 1: Bone Remodeling”, inBone Remodeling and its disorders(2nd edition), London, (Ed. Martin Dunitz), pp. 1-11.
Nociari, M.N., et al., 1998, “A novel one-step, highly sensitive fluorimetric assay to evaluate cell-mediated cytotoxicity,”Journal of Immunological Methods, vol. 213, pp. 157-167.
Raisz, L.G., 1988, “Local and systemic factors in the pathogenesis of osteoporosis,”N. Engl. J. Med., vol. 318, pp. 818-828.
Ralston, S.H., 1997, “Science, Medicine and the Future: Osteoporosis,”Br. Med. J., vol. 315, pp. 469-472.
Rodan, G.A., et al., 1997, “The missing bone,”Cell, vol. 89, pp. 677-680.
Takahashi, N.; et al., 1988, “Osteoblastic cells are involved in osteoclast formation,”Endocrinology, vol. 123, pp. 2600-2602.
van't Hof, R.J., et a;., 1997, “Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity,”J. Bone&Miner. Res., vol. 12, pp. 1797-1804.
Yasuda, H., et al, 1998, “Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro,”Endocrinology, vol. 139, pp. 1329-1337.
Yuan, Y.F. et al, 2000, “Studies on Volatile Oil in Ligusticum Chuanxiong by Supercritical Fluid Extraction”,Zhongguo Yaoxue Zazhi(Beijing) (Clin. Pharm. J. (Beijing), vol. 35, No. 2, pp. 84-87 (with English abstract).
United Kingdom Patent Office Search Report for GB 0310463.5.
United Kingdom Patent Office Search Report for GB 0325259.0.
International Search Report (ISR) for PCT/GB2004/001958.
International Preliminary Report on Patentability (IPRP) for PCT/GB2004/001958.
Baud, V. et al, 1999, “Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain”,Genes Dev., vol. 13, pp. 1297-1308.
Brennan, F.M. et al, 1989, “Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis”,Lancet, vol. 334, pp. 244-247.
Brennan, F.M. et al, 1996, “Cytokines in autoimmunity”,Curr. Opin. Immunol., vol. 8, pp. 872-877.
Brennan, F.M. et al, 1992, “Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints”,Eur. J. Immunol., vol. 22, pp. 1907-1912.
Corey, E.J. et al, 1988, “An efficient and catalytically enantioselective route t
Greig Iain R.
Mohamed Aymen I. I.
Ralston Stuart H.
Van 'T Hof Robert J.
Henley, III Raymond J
Nixon & Vanderhye P.C.
The University Court of the University of Aberdeen
LandOfFree
Ketones and reduced ketones as therapeutic agents for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ketones and reduced ketones as therapeutic agents for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ketones and reduced ketones as therapeutic agents for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4091781